https://www.macrotrends.net/stocks/charts/NVS/nova
Post# of 72440
Novartis had over $7 billion of cash on hand as of last quarter and the stock price is near 3-year highs. Pretty sure they can come up with $50-100 million upfront to lock down what could be the biggest anti-inflammatory drug of the '20s.
And if it's not them, well, there are a dozen other big boys that will want a competing IBD product.